Search

Your search keyword '"van Dongen JJM"' showing total 276 results
Start Over Author "van Dongen JJM"
276 results on '"van Dongen JJM"'

2. Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: a European multicenter study

Author

Najidh, S, primary, Van der Sluijs Gelling, AJ, additional, Cozzio, A, additional, Dobos, G, additional, Bagot, M, additional, Beylot-Barry, M, additional, Guenova, E, additional, Nicolay, J, additional, Lima, M, additional, Ortiz-Romero, PL, additional, Papadavid, E, additional, Pujol, R, additional, Quaglino, P, additional, Stadler, R, additional, Wehkamp, U, additional, Whittaker, S, additional, Van Dongen, JJM, additional, Montero, J Flores, additional, Almeida, J, additional, and Vermeer, MH, additional

Published
2022
Full Text
View/download PDF

22. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia

Author

van Dongen, JJM, Macintyre, EA, Gabert, JA, Delabesse, E, Rossi, V, Saglio, G, Gottardi, E, Rambaldi, A, Dotti, G, Griesinger, F, Parreira, A, Gameiro, P, Diáz, M González, Malec, M, Langerak, AW, San Miguel, JF, and Biondi, A

Published
1999
Full Text
View/download PDF

28. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia

Author

Pongers-Willemse, MJ, Seriu, T, Stolz, F, d’Aniello, E, Gameiro, P, Pisa, P, Gonzalez, M, Bartram, CR, Panzer-Grümayer, ER, Biondi, A, Miguel, JF San, and van Dongen, JJM

Published
1999
Full Text
View/download PDF

36. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

Author

Jos Rijntjes, K. Stamatopoulos, C. Pott, Ramón García-Sanz, Karla Plevová, Giovanni Cazzaniga, Elizabeth Macintyre, Nikos Darzentas, Blanca Scheijen, John Moppett, F. Appelt, Jack Bartram, Eva Froňková, Michael Svatoň, Frederic Davi, Michaela Kotrova, Jan Trka, Simona Songia, Kamila Stránská, Andrea Grioni, Henrik Knecht, Monika Brüggemann, David Gonzalez, Dietrich Herrmann, Michael Hummel, Karol Pál, Anthonie Willem Langerak, Tomáš Reigl, Adam Krejci, van Dongen Jjm, Groenen Pjta, J. Hancock, Peter Stewart, Bystry, Immunology, Ministry of Health of the Czech Republic, Associazione Italiana per la Ricerca sul Cancro, Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, J, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Trka, J, Langerak, A, Gonzalez, D, Pott, C, Bruggemann, M, and Darzentas, N

Subjects
0301 basic medicine, Genetic Markers, Quality Control, Cancer Research, Neoplasm, Residual, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Receptors, Antigen, T-Cell, Immunoglobulins, Human cell line, Computational biology, Biology, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], DNA sequencing, Article, 03 medical and health sciences, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Genetic Marker, Genetics research, Immunoglobulin, Humans, Multiplex, Cancer genetics, Gene Rearrangement, Computational Biology, High-Throughput Nucleotide Sequencing, Reproducibility of Results, Hematology, Gene rearrangement, Minimal residual disease, 3. Good health, Identification (information), 030104 developmental biology, Oncology, Genetic marker, 030220 oncology & carcinogenesis, Primer (molecular biology), Human
Abstract

Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies., This work was supported by Ministry of Health of the Czech Republic, grant no. 16-34272A; computational resources were provided by the CESNET LM2015042 and the CERIT Scientific Cloud LM2015085, provided under the programme “Projects of Large Research, Development, and Innovations Infrastructures”. Analyses in Prague (JT, EF and MS) were supported by Ministry of Health, Czech Republic, grant no. 00064203, and by PRIMUS/17/MED/11. Analyses in the Monza (Centro Ricerca Tettamanti, SS, AG and GC) laboratory were supported by the Italian Association for Cancer Research (AIRC) and Comitato Maria Letizia Verga.

Published
2019

37. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

Author

Knecht, H., Reigl, T., Kotrova, M, Appelt, F., Stewart, P., Bystry, V., Krejčí, A. (Alena), Grioni, A., Pal, K. (Karin) van der, Stranska, K., Plevova, K. (K.), Rijntjes, J., Songia, S., Svaton, M., Fronkova, E., Bartram, J., Scheijen, B. (Blanca), Herrmann, D., Garcia-Sanz, R. (Ramon), Hancock, J., Moppett, J. (John), van Dongen, JJM, Cazzaniga, G. (Gianni), Davi, F. (Frédéric), Groenen, P., Hummel, M. (Michael), Macintyre, E.A. (Elizabeth), Stamatopoulos, K. (Kostas), Trka, J. (Jan), Langerak, A.W. (Anton), Gonzalez, D., Pott, C. (Christiane), Bruggemann, M, Darzentas, N. (Nikos), Knecht, H., Reigl, T., Kotrova, M, Appelt, F., Stewart, P., Bystry, V., Krejčí, A. (Alena), Grioni, A., Pal, K. (Karin) van der, Stranska, K., Plevova, K. (K.), Rijntjes, J., Songia, S., Svaton, M., Fronkova, E., Bartram, J., Scheijen, B. (Blanca), Herrmann, D., Garcia-Sanz, R. (Ramon), Hancock, J., Moppett, J. (John), van Dongen, JJM, Cazzaniga, G. (Gianni), Davi, F. (Frédéric), Groenen, P., Hummel, M. (Michael), Macintyre, E.A. (Elizabeth), Stamatopoulos, K. (Kostas), Trka, J. (Jan), Langerak, A.W. (Anton), Gonzalez, D., Pott, C. (Christiane), Bruggemann, M, and Darzentas, N. (Nikos)

Abstract

Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies.

Published
2019
Full Text
View/download PDF

38. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

Author

Bruggemann, M, Kotrova, M, Knecht, H., Bartram, J., Boudjogrha, M., Bystry, V., Fazio, G., Fronkova, E., Giraud, M., Grioni, A., Hancock, J., Herrmann, D., Jimenez, C. (Cecilia), Krejčí, A. (Alena), Moppett, J. (John), Reigl, T., Salson, M., Scheijen, B. (Blanca), Schwarz, M. (Michael), Songia, S., Svaton, M., van Dongen, JJM, Villarese, P. (Patrick), Wakeman, S., Wright, G, Cazzaniga, G. (Gianni), Davi, F. (Frédéric), Garcia-Sanz, R. (Ramon), Gonzalez, D., Groenen, P., Hummel, M. (Michael), Macintyre, E.A. (Elizabeth), Stamatopoulos, K. (Kostas), Pott, C. (Christiane), Trka, J. (Jan), Darzentas, N. (Nikos), Langerak, A.W. (Anton), Bruggemann, M, Kotrova, M, Knecht, H., Bartram, J., Boudjogrha, M., Bystry, V., Fazio, G., Fronkova, E., Giraud, M., Grioni, A., Hancock, J., Herrmann, D., Jimenez, C. (Cecilia), Krejčí, A. (Alena), Moppett, J. (John), Reigl, T., Salson, M., Scheijen, B. (Blanca), Schwarz, M. (Michael), Songia, S., Svaton, M., van Dongen, JJM, Villarese, P. (Patrick), Wakeman, S., Wright, G, Cazzaniga, G. (Gianni), Davi, F. (Frédéric), Garcia-Sanz, R. (Ramon), Gonzalez, D., Groenen, P., Hummel, M. (Michael), Macintyre, E.A. (Elizabeth), Stamatopoulos, K. (Kostas), Pott, C. (Christiane), Trka, J. (Jan), Darzentas, N. (Nikos), and Langerak, A.W. (Anton)

Abstract

Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was

Published
2019
Full Text
View/download PDF

39. Distribution of subsets of blood monocytic cells throughout life

Author

Damasceno, D., Teodosio, C. (Cristina), van den Bossche, W.B.L., Perez-Andres, M., Arriba-Mendez, S., Munoz-Bellvis, L., Romero, A. (Alfonso), Blanco, JF, Remesal, A., Puig, N, Matarraz, S. (S.), Vicente-Villardon, J.L., van Dongen, JJM, Almeida, J.M.M. (Julia), Orfao, A. (Alberto), Damasceno, D., Teodosio, C. (Cristina), van den Bossche, W.B.L., Perez-Andres, M., Arriba-Mendez, S., Munoz-Bellvis, L., Romero, A. (Alfonso), Blanco, JF, Remesal, A., Puig, N, Matarraz, S. (S.), Vicente-Villardon, J.L., van Dongen, JJM, Almeida, J.M.M. (Julia), and Orfao, A. (Alberto)

Published
2019
Full Text
View/download PDF

40. EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System

Author

van Dongen, JJM, Burg, M. (Mirjam) van der, Kalina, T. (Tomas), Perez-Andres, M., Mejstříková, E. (Ester), Vlkova, M. (Marcela), Lopez-Granados, E., Wentink, M.W.J. (Marjolein), Kienzler, A.K., Philippé, J. (Jan), Sousa, A.E., van Zelm, MC, Blanco, E., Orfao, A. (Alberto), van Dongen, JJM, Burg, M. (Mirjam) van der, Kalina, T. (Tomas), Perez-Andres, M., Mejstříková, E. (Ester), Vlkova, M. (Marcela), Lopez-Granados, E., Wentink, M.W.J. (Marjolein), Kienzler, A.K., Philippé, J. (Jan), Sousa, A.E., van Zelm, MC, Blanco, E., and Orfao, A. (Alberto)

Abstract

Guidelines for screening for primary immunodeficiencies (PID) are well-defined and several consensus diagnostic strategies have been proposed. These consensus proposals have only partially been implemented due to lack of standardization in laboratory procedures, particularly in flow cytometry. The main objectives of the EuroFlow Consortium were to innovate and thoroughly standardize the flowcytometric techniques and strategies for reliable and reproducible diagnosis and classification of PID of the lymphoid system. The proposed EuroFlow antibody panels comprise one orientation tube and seven classification tubes and corresponding databases of normal and PID samples. The 8-color 12-antibody PID Orientation tube (PIDOT) aims at identification and enumeration of the main lymphocyte and leukocyte subsets; this includes naïve pre-germinal center (GC) and antigen-experienced post-GC memory B-cells and plasmablasts. The seven additional 8(-12)-color tubes can be used according to the EuroFlow PID algorithm in parallel or subsequently to the PIDOT for more detailed analysis of B-cell and T-cell subsets to further classify PID of the lymphoid system. The Pre-GC, Post-GC, and immunoglobulin heavy chain (IgH)-isotype B-cell tubes aim at identification and enumeration of B-cell subsets for evaluation of B-cell maturation blocks and specific defects in IgH-subclass production. The severe combined immunodeficiency (SCID) tube and T-cell memory/effector subset tube aim at identification and enumeration of T-cell subsets for assessment of T-cell defects, such as SCID. In case of suspicion of antibody deficiency, PIDOT is preferably directly combined with the IgH isotype tube(s) and in case of SCID suspicion (e.g., in newborn screening programs) the PIDOT is preferably directly combined with the SCID T-cell tube. The proposed ≥8-color antibody panels and corresponding reference databases combined with the EuroFlow PID algorithm are designed to provide fast, sensitive and cost-effect

Published
2019
Full Text
View/download PDF

41. The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System

Author

Burg, M. (Mirjam) van der, Kalina, T. (Tomas), Perez-Andres, M., Vlkova, M. (Marcela), Lopez-Granados, E., Blanco, E., Bonroy, C., Sousa, A.E., Kienzler, A.K., Wentink, M.W.J. (Marjolein), Mejstriikovaa, E., Siinkorova, V., Stuchly, J., van Zelm, MC, Orfao, A. (Alberto), van Dongen, JJM, Burg, M. (Mirjam) van der, Kalina, T. (Tomas), Perez-Andres, M., Vlkova, M. (Marcela), Lopez-Granados, E., Blanco, E., Bonroy, C., Sousa, A.E., Kienzler, A.K., Wentink, M.W.J. (Marjolein), Mejstriikovaa, E., Siinkorova, V., Stuchly, J., van Zelm, MC, Orfao, A. (Alberto), and van Dongen, JJM

Abstract

In the rapidly evolving field of primary immunodeficiencies (PID), the EuroFlow consortium decided to develop a PID orientation and screening tube that facilitates fast, standardized, and validated immunophenotypic diagnosis of lymphoid PID, and allows full exchange of data between centers. Our aim was to develop a tool that would be universal for all lymphoid PIDs and offer high sensitivity to identify a lymphoid PID (without a need for specificity to diagnose particular PID) and to guide and prioritize further diagnostic modalities and clinical management. The tube composition has been defined in a stepwise manner through several cycles of design-testing-evaluationredesign in a multicenter setting. Equally important appeared to be the standardized preanalytical procedures (sample preparation and instrument setup), analytical procedures (immunostaining and data acquisition), the software analysis (a multidimensional view based on a reference database in Infinicyt software), and data interpretation. This standardized EuroFlow concept has been tested on 250 healthy controls and 99 PID patients with defined genetic defects. In addition, an application of new EuroFlow software tools with multidimensional pattern recognition was designed with inclusion of maturation pathways in multidimensional patterns (APS plots). The major advantage of the EuroFlow approach is that data can be fully exchanged between different laboratories in any country of the world, which is especially of interest for the PID field, with generally low numbers of cases per center.

Published
2019
Full Text
View/download PDF

42. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia

Author

Sedek, L, Theunissen, P, Sobral da Costa, E, van der Sluijs-Gelling, A, Mejstrikova, E, Gaipa, G, Sonsala, A, Twardoch, M, Oliveira, E, Novakova, M, Buracchi, C, van Dongen, J, Orfao, A, van der Velden, V, Szczepanski, T, van Dongen, JJM, van der Velden, VHJ, Sedek, L, Theunissen, P, Sobral da Costa, E, van der Sluijs-Gelling, A, Mejstrikova, E, Gaipa, G, Sonsala, A, Twardoch, M, Oliveira, E, Novakova, M, Buracchi, C, van Dongen, J, Orfao, A, van der Velden, V, Szczepanski, T, van Dongen, JJM, and van der Velden, VHJ

Abstract

Background: Optimal discrimination between leukemic blasts and normal B-cell precursors (BCP) is critical for treatment monitoring in BCP acute lymphoblastic leukemia (ALL); thus identification of markers differentially expressed on normal BCP and leukemic blasts is required. Methods: Multicenter analysis of CD73, CD86 and CD304 expression levels was performed in 282 pediatric BCP-ALL patients vs. normal bone marrow BCP, using normalized median fluorescence intensity (nMFI) values. Results: CD73 was expressed at abnormally higher levels (vs. pooled normal BCP) at diagnosis in 71/108 BCP-ALL patients (66%), whereas CD304 and CD86 in 119/202 (59%) and 58/100 (58%) patients, respectively. Expression of CD304 was detected at similar percentages in common-ALL and pre-B-ALL, while found at significantly lower frequencies in pro-B-ALL. A significant association (p = 0.009) was found between CD304 expression and the presence of the ETV6-RUNX1 fusion gene. In contrast, CD304 showed an inverse association with MLL gene rearrangements (p = 0.01). The expression levels of CD73, CD86 and CD304 at day 15 after starting therapy (MRD15) were stable or higher than at diagnosis in 35/37 (95%), 40/56 (71%) and 19/41 (46%) cases investigated, respectively. This was also associated with an increased mean nMFI at MRD15 vs. diagnosis of +24 and +3 nMFI units for CD73 and CD86, respectively. In addition, gain of expression of CD73 and CD86 at MRD15 for cases that were originally negative for these markers at diagnosis was observed in 16% and 18% of cases, respectively. Of note, CD304 remained aberrantly positive in 63% of patients, despite its levels of expression decreased at follow-up in 54% of cases. Conclusions: Here we show that CD73, CD86 and CD304 are aberrantly (over)expressed in a substantial percentage of BCP-ALL patients and that their expression profile remains relatively stable early after starting therapy, supporting their potential contribution to improved MRD analysis by fl

Published
2019

44. Delineating Human B Cell Precursor Development With Genetically Identified PID Cases as a Model

Author

Wentink, Marjolein, Kalina, T, Perez-Andres, M, Molina, LD, Ijspeert, Hanna, Kavelaars, François, Lankester, AC, Lecrevisse, Q, van Dongen, JJM, Orfao, A, van der Burg, Mirjam, Wentink, Marjolein, Kalina, T, Perez-Andres, M, Molina, LD, Ijspeert, Hanna, Kavelaars, François, Lankester, AC, Lecrevisse, Q, van Dongen, JJM, Orfao, A, and van der Burg, Mirjam

Published
2019

45. EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets

Author

Flores-Montero, J, Grigore, G, Fluxa, R, Hernandez, J, Fernandez, P, Almeida, J, Munoz, N, Bottcher, S, Sedek, L, van der Velden, Vincent, Barrena, S, Hernandez, A, Paiva, B, Lecrevisse, Q, Lima, M, Santos, AH, van Dongen, JJM, Orfao, A, Flores-Montero, J, Grigore, G, Fluxa, R, Hernandez, J, Fernandez, P, Almeida, J, Munoz, N, Bottcher, S, Sedek, L, van der Velden, Vincent, Barrena, S, Hernandez, A, Paiva, B, Lecrevisse, Q, Lima, M, Santos, AH, van Dongen, JJM, and Orfao, A

Published
2019

46. Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples

Author

van der Velden, Vincent, Flores-Montero, J, Perez-Andres, M, Martin-Ayuso, M, Crespo, O, Blanco, E, Kalina, T, Philippe, J, Bonroy, C, de Bie, Maaike, te Marvelde, Jeroen, Teodosio, C, Mateos, AC, Kanderova, V, van der Burg, Mirjam, Van Hoof, D, van Dongen, JJM, Orfao, A, van der Velden, Vincent, Flores-Montero, J, Perez-Andres, M, Martin-Ayuso, M, Crespo, O, Blanco, E, Kalina, T, Philippe, J, Bonroy, C, de Bie, Maaike, te Marvelde, Jeroen, Teodosio, C, Mateos, AC, Kanderova, V, van der Burg, Mirjam, Van Hoof, D, van Dongen, JJM, and Orfao, A

Published
2019

47. Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies

Author

Blanco, E, Perez-Andres, M, Arriba-Mendez, S, Serrano, C, Criado, I, Del Pino-Molina, L, Silva, S, Madruga, I, Bakardjieva, M, Martins, C, Serra-Caetano, A, Romero, A, Contreras-Sanfeliciano, T, Bonroy, C, Sala, F, Martin, A, Bastida, JM, Lorente, F, Prieto, C, Davila, I, Marcos, M, Kalina, T, Vlkova, M, Chovancova, Z, Cordeiro, AI, Philippe, J, Haerynck, F, Lopez-Granados, E, Sousa, AE, van der Burg, Mirjam, van Dongen, JJM, Orfao, A, Blanco, E, Perez-Andres, M, Arriba-Mendez, S, Serrano, C, Criado, I, Del Pino-Molina, L, Silva, S, Madruga, I, Bakardjieva, M, Martins, C, Serra-Caetano, A, Romero, A, Contreras-Sanfeliciano, T, Bonroy, C, Sala, F, Martin, A, Bastida, JM, Lorente, F, Prieto, C, Davila, I, Marcos, M, Kalina, T, Vlkova, M, Chovancova, Z, Cordeiro, AI, Philippe, J, Haerynck, F, Lopez-Granados, E, Sousa, AE, van der Burg, Mirjam, van Dongen, JJM, and Orfao, A

Published
2019

48. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

Author

Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, van der Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, JJM, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, EA, Stamatopoulos, K, Trka, J, Langerak, Ton, Gonzalez, D, Pott, C, Bruggemann, M, Darzentas, N, Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, van der Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, JJM, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, EA, Stamatopoulos, K, Trka, J, Langerak, Ton, Gonzalez, D, Pott, C, Bruggemann, M, and Darzentas, N

Published
2019

49. Distribution of subsets of blood monocytic cells throughout life

Author

Damasceno, D, Teodosio, C, Bossche, Wouter, Perez-Andres, M, Arriba-Mendez, S, Munoz-Bellvis, L, Romero, A, Blanco, JF, Remesal, A, Puig, N, Matarraz, S, Vicente-Villardon, JL, van Dongen, JJM, Almeida, J, Orfao, A, Damasceno, D, Teodosio, C, Bossche, Wouter, Perez-Andres, M, Arriba-Mendez, S, Munoz-Bellvis, L, Romero, A, Blanco, JF, Remesal, A, Puig, N, Matarraz, S, Vicente-Villardon, JL, van Dongen, JJM, Almeida, J, and Orfao, A

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results